Banasiak Hanna, Pawliczak Rafał
Department of Immunopathology, Division of Allergology, Immunology and Dermatology, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.
Postepy Dermatol Alergol. 2020 Dec;37(6):879-889. doi: 10.5114/ada.2020.102102. Epub 2021 Jan 6.
Asthma is a complex condition characterized by the presence of chronic inflammation in the lower respiratory tract resulting in many disturbing symptoms. The study of the clinical profile of the population with asthma allows us to understand a trend of a specific disease taking into account several indicators and its clinical characteristics.
Evaluation of the clinical profile of patients with chronic bronchial asthma in Poland.
The study included 10400 adult patients, of both sexes, diagnosed with chronic bronchial asthma who started therapy based on inhaled glucocorticosteroids accompanied by salmeterol, and 52 allergists. The examination was performed in a doctor's surgery. Standardized questionnaire interviews were used in order to carry out the procedure.
The age of the patients ranged from 18 up to 97 years. Most of them suffer from overweight and obesity. 45.3% of the patients smoked cigarettes or declared to be passive smokers. Current asthma control was poor: over 56% of the patients suffered from diurnal symptoms more often than twice a week, almost 55% from nocturnal symptoms, in 72% of the patients' physical activity was limited, whereas 57% required immediate treatment. Most commonly used drugs were inhaled glucocorticosteroids and short acting β2-mimetics. After treatment change, fewer patients suffered from asthma symptoms.
Adjusting the therapy according to the current guidelines and to the patient's needs helps to improve asthma control.
哮喘是一种复杂的病症，其特征是下呼吸道存在慢性炎症，会导致许多令人困扰的症状。对哮喘患者群体的临床特征进行研究，有助于我们在考虑多个指标及其临床特征的情况下，了解一种特定疾病的发展趋势。
评估波兰慢性支气管哮喘患者的临床特征。
该研究纳入了10400名成年患者，男女皆有，均被诊断为慢性支气管哮喘，且开始接受基于吸入糖皮质激素联合沙美特罗的治疗，同时纳入了52名过敏症专科医生。检查在医生的诊所进行。为实施该程序，采用了标准化问卷调查访谈。
患者年龄在18岁至97岁之间。他们中的大多数患有超重和肥胖症。45.3%的患者吸烟或宣称是被动吸烟者。目前哮喘控制不佳：超过56%的患者白天症状每周发作超过两次，近55%的患者有夜间症状，72%的患者身体活动受限，而57%的患者需要立即治疗。最常用的药物是吸入糖皮质激素和短效β2-受体激动剂。治疗方案调整后，哮喘症状患者减少。
根据当前指南和患者需求调整治疗有助于改善哮喘控制。
